Phase 2Not yet recruiting
Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML
A Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in Acute Myeloid Leukemia Maintenance.
- Sponsor
- Rutgers, The State University of New Jersey (Academic or other)
- Enrollment
- 41 planned
- Conditions
- Acute Myeloid Leukaemia (AML)
- Interventions
- Venetoclax, Decitabine/Cedaruridine; decitabine/cedazuridine
- Ages
- adults, older adults
- Registry
- NCT07867626
Full record on ClinicalTrials.gov
From the registry
To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)
Primary outcomes
- Primary Outcome
History
Study completion expected
Primary completion expected
Registered
Started